SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference

SynAct Pharma AB ("SynAct") today announced that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Virtual Series, on May 5.

The presentation will be available via SynAct’s website: www.synactpharma.com.

More information about the event is available at the organizer’s website: https://www.kempen.com/en/securities/events/life-sciences-conference

The information was submitted, through the agency of the contact persons below, for publication on April 30, 2021.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                Thomas Jonassen

CEO, SynAct Pharma AB                                                               CSO, SynAct Pharma AB

Phone: +45 28 44 75 67                                                                 Phone: +45 40 15 66 69
 

Mail: joo@synactpharma.com                                                        Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.